Description: Session 6E: Medicaid Redetermination and ARP - Impacts on ACA Individual Markets

Description: How well can we predict ACA HHS Risk Adjustment Data Validation (HRADV) results? Put another way, how susceptible is the current HRADV process to small sample volatility? What potential remedies are there to the current model's shortcomings? Every plan, regardless of how many members they have above the 1000 minimum, count equally if they qualify for an HRADV with how the result is interpreted, and the subsequent HRADV risk transfer ($330M in 2023).

Description: Medicare Advantage plans have been in the market for two decades. In this session, we survey the landscape changes from 2006 up to now, which include but not limited to the changes of enrollment, plan types, big players' market share, policies, and how players as well as beneficiaries react to the changes. This session intends to provide general MA knowledge and history to the audience with or without Medicare Advantage background.

Description: A new wave of biosimilar launches is creating downward pressure on average sales prices (ASPs), disrupting reimbursement to providers, providing opportunities and challenges to payers and GPOs, and upending the gross-to-net math for manufacturers. In this session, we will explore the implications of the ASP death spiral on the drug supply chain and its interplay with price transparency efforts.

Description: Do your interests stop at your actuarial responsibilities of risk analysis, trend and rate submission? Reach beyond your role as the actuary. Become a leader-manager within the Market Segment Team and a trusted advisor to the P&L leader. Choosing your approach to working with the P&L leader determines your influence and impact on segment sustainability and success

Description: Is 2024 the year you need to implement U.S. GAAP Long-Duration Targeted Improvements for individual health insurance products? In this session, we will discuss implementation and the importance of working with accountants and IT to ensure a successful implementation. Some requirements will be a surprise to health actuaries.

Description: Sarah Rockhill, MPH, Geospatial Epidemiologist at CDC will discuss the latest in the Public Health 3.0 model in which leaders serve as Chief Health Strategists, partnering across multiple sectors and leveraging data and resources to address social, environmental, and economic conditions that affect health and health equity.

Description: Court is in session and you are the jury! Follow along as challenging aspects of actuarial professionalism are explored in a court-like setting. Deliberate among your peers based on what you already know from your own experience as well as what you learn in this session, and then deliver your verdict accordingly.

Description: Explore the dynamic intersection of health insurance data and diverse industries beyond traditional health insurance providers. This session will delve into how life science companies, pharmaceutical manufacturers, device manufacturers, and others leverage health insurance data to drive innovation and decision-making.

Description: The Patient Protection and Affordable Care Act (ACA) begins its second decade in a presidential election year. With a decade of experience, opinions on the law's policy efficacy are now rooted in data rather than forecasts. Hear two highly regarded policy experts discuss and debate various policy considerations related to the ACA and other current policy concerns in an actuary-moderated debate-style discussion.